- Apply online when available. Turnaround time is substantially quicker—weeks rather than months—for online applications than for mailed or faxed applications.
- Call the drug company directly with questions. PAP staff are responsive and great at troubleshooting. Calling is easier than finding answers on drug company websites, especially because PAP information is often buried beneath multiple clicks.
- Involve one of your team members to follow up with the patient and assist with the application process as needed. This is especially important for non-English-speaking patients because PAP phone services all start with prompts in English.
- Send in the provider part of the PAP application at the time of visit. Nearly all applications require a signed form from the prescriber as part of the application. These can be found on PAP websites.
- Encourage the patient to follow up with the drug company every two weeks to confirm receipt of all required documents and to check on status. Drugs won’t be approved if any part of the application is missing, but companies don’t typically notify patients about missing paperwork. Delays in approval notification are also common, and the patient typically needs to call to arrange delivery of the first shipment. It’s frustrating to find out a free drug supply has been approved for months, unbeknownst to the patient or provider.
- Remind the patient to call the drug company directly to set up refill deliveries. Some companies allow patients to sign up to receive text message reminders about refills.
- Plan ahead. Most drug companies approve free drug supplies for one year, although some may approve the drug for up to three years. If therapy is to be continued via a PAP, the patient must reapply one to three months before their approval lapses.
Figure 1. PAP phone numbers as of January 2022.
Patient Assistance Program |
Medications | Phone number |
My AbbVie Assist |
adalimumab (Humira) upadacitinib (Rinvoq) risankizumab (Skyrizi) |
(800) 222-6885 |
Amgen Safety Net Foundation |
etanercept (Enbrel) apremilast (Otezla) |
(888) 762-6436 |
Pfizer PAP (Xelsource) |
tofacitinib (Xeljanz) |
(844) 935-5269 |
Novartis Patient Assistance Foundation |
secukinumab (Cosentyx) mycophenolate sodium (Myfortic) canakinumab (Ilaris) |
(800) 277-2254 |
J&J Patient Assistance Foundation |
ustekinumab (Stelara) guselkumab (Tremfya) golimumab (Simponi) infliximab (Remicade) |
(800) 652-6227 |
Bristol Meyers Squibb Patient Assistance Foundation |
abatacept (Orencia) |
(800) 736-0003 |
Genentech Patient Foundation |
tocilizumab (Actemra) rituximab (Rituxan) |
(888) 941-3331
Related ArticlesCombine With Medicare Part D to Help Patients Afford PrescriptionsAccording to the 2003 U.S. Census, 29 million people in the United States make less than 200% of the federal poverty level and have no health insurance. Many persons have difficulty affording prescribed medications. In addition to Medicare Part D, there are more than 350 public and private patient assistance programs, including programs by pharmaceutical companies, that help patients pay for prescriptions. Colcrys Approval Triggers QuestionsSome rheumatologists question the depth of research and the approval’s implications for patient access Drug Assistance Programs Offer Little Charity to Uninsured(Reuters Health)—Many patients who receive assistance from charities set up to defray prescription drugs costs may already have insurance that covers most the cost for their medications, a U.S. study suggests. Researchers examined data on the six largest independent charities offering patient assistance programs through 274 different disease-specific programs. These programs had total revenue ranging… U.S. Uninsured Rate Up by Most in Nearly a DecadeWASHINGTON (Reuters)—The number of Americans without health insurance rose by 3.2 million people between 2016 and 2017, or 1.3% points to 12.2%, according to a Gallup poll released on Tuesday, the biggest jump in the uninsured rate in nearly a decade.1 Several factors likely contributed to the jump, Gallup said, including attempts by Republicans, who… |